Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Nkarta, Inc. (Nasdaq: NKTX) presented four preclinical data abstracts at the SITC 36th Annual Meeting, highlighting advancements in its NK cell therapy platform. The research demonstrates enhanced NK cell ability to target tumors through innovative approaches, including gene-editing strategies. Notably, the combination of CD70 CAR and CISH knockout showed increased cytotoxicity and persistence of NK cells. Additionally, methods for large-scale expansion of NK cells could lead to efficient off-the-shelf therapies. These findings underscore Nkarta's ongoing collaboration with CRISPR Therapeutics and its commitment to advancing cancer treatments.
Nkarta, Inc. (Nasdaq: NKTX) reported its third-quarter 2021 results, highlighting key advancements in its clinical trials. The company anticipates initial data from the Phase 1 trial of NKX101 in AML and MDS in the first half of 2022, while also announcing the successful dosing of patients in the NKX019 trial for B cell malignancies. Financially, Nkarta had cash equivalents of $259.8 million as of September 30, 2021, with R&D expenses totaling $16.6 million. The net loss for the quarter was $22.4 million, or $0.68 per share, but guidance suggests operational funding through at least the second half of 2023.
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical firm focused on engineered NK cell therapies for cancer, announced its participation in several upcoming investor conferences. Notable events include the Cowen 5th Annual IO Next Summit on November 15, 2021, at 11:15 a.m. ET, the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 2:00 p.m. ET, and the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 4:20 p.m. ET. Each session will be webcast live and available for replay on Nkarta's website.
Nkarta, Inc. announced the initiation of a Phase 1 clinical trial for NKX019 aimed at treating advanced B-cell malignancies. This investigational NK cell immunotherapy targets CD19, with initial data expected in 2022. The company also updated its timeline for NKX101, another CAR NK cell therapy for AML and MDS, anticipating initial data in the first half of 2022. Nkarta is producing the NKX019 clinical supply at its South San Francisco facility, aiming to provide an effective off-the-shelf treatment option for patients.
Nkarta, Inc. (Nasdaq: NKTX) announced four upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, detailing advancements in engineered natural killer (NK) cell therapies. Key highlights include the potential clinical applications of CRISPR/Cas9 technologies and donor selection algorithms for next-generation NK cells. The presentations aim to enhance the expansion of engineered NK cells, potentially allowing a single donor to supply a lifetime's worth of commercial product. Full abstracts will be available on November 9, 2021.
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on NK cell therapies for cancer, announced participation in the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 4:00 p.m. ET. A live webcast of the presentation will be accessible on Nkarta’s website, with an archived replay available for approximately four weeks. Nkarta is committed to developing off-the-shelf NK cell therapies through innovative manufacturing and engineering techniques to enhance tumor targeting and sustained activity in cancer patients.
Nkarta, Inc. (Nasdaq: NKTX) reported its Q2 2021 results, highlighting progress in NK cell therapies. The company aims to present initial data from its NKX101 clinical trial by year's end, while patient dosing for NKX019 is expected to begin in 2H 2021. Nkarta has formed a collaboration with CRISPR Therapeutics for developing gene-edited therapies and established a new manufacturing headquarters to support trial and commercial efforts. As of June 30, 2021, cash reserves stood at $280.3 million, with a net loss of $21.5 million.
Nkarta, Inc. (Nasdaq: NKTX) has signed a lease for an 88,000 square foot facility in South San Francisco, intended for scaled manufacturing and to serve as the company headquarters. This expansion aims to support Nkarta’s engineering NK cell therapy candidates and enhance clinical programs NKX101 and NKX019. The facility, expected to be operational by late 2023, will enable commercial-scale production for clinical trials. Nkarta's focus on cost-effective therapies aligns with their goal to improve access for cancer patients.
Nkarta, a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer, announced its participation in the Raymond James Human Health Innovation Conference. The event is scheduled for June 21, 2021, featuring a fireside chat presentation at 3:20 p.m. ET. A live webcast will be available on Nkarta's website, with a replay accessible for approximately four weeks thereafter. The company is advancing allogeneic NK cell therapies through innovative manufacturing processes designed to enhance tumor targeting and persistence.
Nkarta, Inc. (Nasdaq: NKTX) announced that CEO Paul Hastings has been elected Chair of the Biotechnology Innovation Organization (BIO) Board of Directors for the 2021-2022 term. Hastings, recognized as a biotech pioneer, has a history as a patient advocate and innovative leader. BIO, the largest biotechnology advocacy group, focuses on advancing healthcare and environmental products. Hastings' election is expected to enhance support for innovation and advocacy within the biotech industry, as he brings over two decades of leadership experience to his new role.